Related Experiment Video
Updated: Jan 20, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors
Ahmad Hanif1, Manu Pandey1, Sumera Khan2
1Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Abstract:
Introduction: Renal cell carcinoma (RCC) with sarcomatoid component carries a poor prognosis. Immune checkpoint inhibitors (CPIs) have been approved for the treatment of metastatic RCC, but their efficacy in patients with sarcomatoid component is not known. Materials and Methods: We conducted a retrospective chart review of 30 consecutive patients at our center who were treated for metastatic RCC with sarcomatoid component. Results: Ten patients were treated with CPI group while 20 patients were in No-CPI group. There were no significant differences in age, sex, race, and stage at diagnosis between the two groups. After a median follow-up of 35 months, 3 of 10 patients in CPI arm and 5 of 20 patients in No-CPI group were alive. The median overall survival was 33.8 m in immunotherapy group compared to 8.8 m in nonimmunotherapy group (p = .001). Discussion: In our experience, CPI therapy resulted in better outcomes compared to traditional therapy with molecular-targeted agents or chemotherapy in these patients.
Insights
Immune checkpoint inhibitors (CPIs) show promise in treating metastatic renal cell carcinoma (RCC) with a sarcomatoid component. This study found CPI therapy significantly improved overall survival in these patients compared to traditional treatments.
Area of Science:
- Oncology
- Immunotherapy
- Genitourinary Cancers
Background:
- Metastatic renal cell carcinoma (RCC) with sarcomatoid features has a poor prognosis.
- Immune checkpoint inhibitors (CPIs) are approved for metastatic RCC, but their effectiveness in sarcomatoid subtypes is unclear.
Purpose of the Study:
- To evaluate the efficacy of CPIs in patients with metastatic RCC and sarcomatoid component.
- To compare overall survival between patients treated with CPIs and those receiving traditional therapies.
Main Methods:
- Retrospective chart review of 30 consecutive patients with metastatic RCC and sarcomatoid component.
- Patients were divided into two groups: CPI treatment and no CPI treatment.
- Median follow-up was 35 months.
Main Results:
- Median overall survival was 33.8 months in the CPI group versus 8.8 months in the non-CPI group (p = .001).
- 3 out of 10 patients in the CPI arm survived, compared to 5 out of 20 in the non-CPI group.
- No significant differences in baseline characteristics were observed between the groups.
Conclusions:
- CPI therapy appears to improve outcomes in patients with metastatic RCC and sarcomatoid component.
- CPIs represent a potentially superior treatment option compared to traditional therapies for this patient population.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:38What is the Immune System?
01:40Cell-mediated Immune Responses
01:23Cells of the Adaptive Immune Response
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...